Bridgefront Capital’s Immunocore IMCR Stock Holding History

Bridgefront Capital’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,707	Closed	-$271K	–	680
2024 Q3	$271K	Buy	+8,707	New	+$317K	0.1%	360

Other funds holding IMCR

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Bridgefront Capital's IMCR Position: Q4 2024 in Review

Bridgefront Capital sold out of Immunocore (IMCR) in Q4 2024, closing a stake of 8,707 shares — an estimated $271K sold.

Bridgefront Capital first reported a position in IMCR in Q3 2024 and held it in 1 quarter. The position peaked at $271K in Q3 2024. 115 funds tracked by Wall St. Rank hold IMCR as of Q4 2024.

Bridgefront Capital reported no remaining Immunocore position as of Q4 2024 after selling out during the quarter.
Bridgefront Capital sold 8,707 Immunocore shares in Q4 2024, an estimated $271K.
Bridgefront Capital first reported a position in Immunocore in Q3 2024 and held it in 1 quarter.
Bridgefront Capital's Immunocore position peaked at $271K in Q3 2024.
115 funds tracked by Wall St. Rank held Immunocore as of Q4 2024.

Based on Bridgefront Capital's 13F filing for Q4 2024, filed 14 Feb 2025.